

A Comprehensive Review on the Application of Mesenchymal Stem Cell in The Treatment of ALS Patients

Shahbeigi Saeed

Department of Radiology, The First Affiliated Hospital of Sun Yat-Sen University, China

Abstract

Amyotrophic Lateral Sclerosis (ALS) is a malignant disorder in body which impairs motor neuron activity of body and eventually causes death. Although, many researches have been allocated to discover the molecular basis of ALS, but no definite cure of this fatal disease has been found until present time. The scientific revolution of application of stem cells in medicine has encouraged utilization of such technology to exploit the related medical benefits in ALS therapeutics. The purpose of this review is to explore in detail of any available findings of pre-clinical and clinical expeditions of the medical effects of Mesenchymal Stem Cells (MSCs) on ALS. The review encircles in detail the medical research findings on the immune effects of MSCs in ALS treatment and also the related clinical trial. Also the wide range of overall world impact of the disease at present time and in the future is reviewed. permeability parameters and ADC, irrespective of the brain

We describe a case of a 13 years old girl who developed L3-L4 spondylodiscitis by Staphylococcus aureus agent. After 2 months of levofloxacin therapy she developed intracranial hypertension, without any evidence of intracerebral mass or hydrocephalus at CT scan and MRI. The levofloxacin therapy was stopped and the symptoms disappeared after same days.

Received date: March 08, 2022 | **Accepted date:** March 15, 2022 | **Published date:** March 23, 2022

Biography

Shahbeigi Saeed is a Specialist in Neurology; he has worked for 10 years in the Institute of Neurology of Havana, Cuba. He has worked with Electron Microscopy on Schizophrenia for 32 years. He was awarded with the

International Price of the Stanley Foundation Award Program and for the Professional Committee to work as a fellowship position in the Laboratory of the Central Nervous System Studies, National Institute of Neurological Diseases and Stroke under Dr. Joseph Gibbs for a period of 6 months, National Institute of Health, Bethesda, Washington DC USA.